Perk (Protein Kinase R Like Er Kinase) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PERK (Protein Kinase R-like ER Kinase, also known as EIF2AK3) is a key sensor of endoplasmic reticulum (ER) stress and a critical regulator of the unfolded protein response (UPR). PERK is a type I transmembrane protein localized to the ER membrane that activates the Integrated Stress Response (ISR) when misfolded proteins accumulate in the ER lumen (Hetz & Glimour, 2009; Wang & Kaufman, 2016). PERK activation has been implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease, making it an important therapeutic target (Kim et al., 2020; Liu et al., 2019).
¶ Gene and Protein Structure
The EIF2AK3 gene (ENSG00000168207) is located on chromosome 2p22.2 and consists of 18 exons. It encodes the PERK protein, a large type I transmembrane kinase.
¶ Protein Domain Architecture
PERK is a 1254-amino acid protein with the following structural features:
- Luminal stress-sensing domain (residues 1-568): Binds unfolded proteins through its interaction with the chaperone BiP (GRP78)
- Transmembrane helix (residues 569-591): Anchors PERK to the ER membrane
- Cytoplasmic serine/threonine kinase domain (residues 592-1254): Contains the active site and undergoes autophosphorylation upon activation
- eIF2α phosphorylation site: PERK phosphorylates eIF2α at Ser^51 to attenuate global translation
Under normal conditions, PERK's luminal domain is bound by BiP (GRP78), which prevents dimerization and kinase activation. During ER stress, BiP dissociates to bind misfolded proteins, allowing PERK to dimerize and autophosphorylate (Bertolotti et al., 2000; Kimata et al., 2008).
PERK is one of four eIF2α kinases that activate the Integrated Stress Response (ISR). The ISR coordinates cellular adaptation to various stressors:
- PERK: Activated by ER stress (misfolded proteins, calcium depletion, hypoxia)
- GCN2: Activated by amino acid deprivation
- PKR: Activated by viral infection
- HRI: Activated by heme deficiency
PERK-mediated eIF2α phosphorylation causes:
- Global translation attenuation: Reduces protein load on the stressed ER
- Selective translation of stress-response proteins: ATF4, CHOP, GADD34, XBP1
Prolonged PERK activation leads to apoptosis through:
- CHOP upregulation: Pro-apoptotic transcription factor
- Bcl-2 family modulation: Decreased anti-apoptotic proteins
- Calcium homeostasis disruption: Mitochondrial apoptosis pathway
PERK activation is a hallmark of AD brain pathology:
ER Stress:
Translational Dysregulation:
- Global translation is impaired in AD brain
- PERK-mediated eIF2α phosphorylation contributes to synaptic protein loss
- Restoring translation with ISR inhibitors improves synaptic function in AD models
Synaptic Dysfunction:
- PERK activation contributes to synaptic loss in AD
- Inhibiting PERK protects against Aβ-induced synaptic damage
PERK plays complex roles in PD:
ER Stress:
Dopaminergic Neuron Vulnerability:
- PERK-mediated translational attenuation impairs protein homeostasis
- Chronic PERK activation leads to apoptosis of dopaminergic neurons
Therapeutic Potential:
- PERK inhibition protects against α-syn-induced toxicity (Bellucci et al., 2011)
- However, complete PERK loss may be detrimental due to loss of adaptive UPR
- PERK is activated in ALS motor neurons and glia
- Mutations in SOD1, FUS, and C9orf72 all induce ER stress and PERK activation
- PERK activation contributes to motor neuron death in ALS models
- However, PERK also attempts adaptive responses, complicating therapeutic targeting
- Mutant huntingtin protein induces ER stress
- PERK activation is increased in HD models and patient tissue
- PERK-mediated translational repression contributes to neuronal dysfunction
- ISR modulators show promise in HD preclinical models
¶ Ischemia and Stroke
- PERK is rapidly activated following cerebral ischemia
- Contributes to both adaptive responses and excitotoxic cell death
- PERK inhibition may reduce post-ischemic brain damage
Small molecule PERK inhibitors are under development:
- GSK2656157: First-generation PERK inhibitor, showed efficacy in cancer models but limited BBB penetration
- AMG 47: More brain-penetrant PERK inhibitor
- Compound 43: Selective PERK inhibitor with improved CNS penetration
- PERK has both protective and harmful effects depending on context and duration
- Complete PERK inhibition may impair adaptive UPR
- Timing of intervention is critical (early vs. late disease)
- Selectivity over other eIF2α kinases is important
Rather than direct PERK inhibition, alternative approaches include:
- ISRIB (Integrated Stress Response Inhibitor): Stabilizes eIF2B to bypass eIF2α phosphorylation effects
- eIF2α phosphatase inhibitors: Maintain translational recovery
- Modulators of upstream ER stress: Target misfolded protein handling
- PERK inhibition combined with other ER stress modulators
- Targeting downstream effectors (CHOP, ATF4)
- Combined modulation of UPR branches (PERK, IRE1, ATF6)
The study of Perk (Protein Kinase R Like Er Kinase) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hetz, C., & Glimour, R. (2009). The unfolded protein response: From stress signaling to cortical degeneration. Brain Research, 1298, 115-126. DOI: 10.1016/j.brainres.2009.07.019
- Wang, M., & Kaufman, R.J. (2016). Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature, 529(7586), 326-335. DOI: 10.1038/nrm.2016.81
- Kim, H.J., et al. (2020). PERK as a therapeutic target for neurodegenerative diseases. Trends in Cell Biology, 30(8), 587-598. DOI: 10.1016/j.tcb.2020.02.006
- Liu, Y., et al. (2019). Targeting PERK signaling with small molecules: A new therapeutic approach for neurodegenerative diseases. Trends in Pharmacological Sciences, 40(11), 786-798. DOI: 10.1016/j.tips.2019.08.003
- Bertolotti, A., et al. (2000). Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nature Cell Biology, 2(6), 326-332. DOI: 10.1038/35021049
- Kimata, Y., et al. (2008). regulatory mechanisms of the unfolded protein response. Current Opinion in Cell Biology, 20(6), 589-596. DOI: 10.1016/j.tcb.2008.01.003
- Costa, R.O., et al. (2012). Amyloid beta-induced ER stress is enhanced under insulin resistance conditions. Neurobiology of Aging, 33(4), 825.e11-825.e22. DOI: 10.1016/j.neurobiolaging.2011.09.030
- Colla, E., et al. (2019). ER stress and Parkinson's disease: Pathological interventions that modulate the secretory pathway. Journal of Biological Chemistry, 294(45), 16851-16861. DOI: 10.1074/jbc.REV119.007790
- Bellucci, A., et al. (2011). Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease. Neurobiology of Aging, 32(12), 2194-2205. DOI: 10.1016/j.neurobiolaging.2010.12.016